First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)
about
Clinical development of Ebola vaccinesDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsA global approach to HIV-1 vaccine developmentCryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses.A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Adenoviral vectors as novel vaccines for influenza.Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.Novel directions in HIV-1 vaccines revealed from clinical trialsProtection of non-human primates against rabies with an adenovirus recombinant vaccine.Nonreplicating vectors in HIV vaccines.The influence of delivery vectors on HIV vaccine efficacyFirst-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Novel vaccine vectors for HIV-1.Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansManipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoCentralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by VectorizationDifferential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceCharacterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesNovel HIV vaccine strategies: overview and perspective.Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infectionConserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Ebola virus vaccine: benefit and risks of adenovirus-based vectors.The state of gene therapy research in Africa, its significance and implications for the future.DNA-based influenza vaccines as immunoprophylactic agents toward universality.Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.Adenoviral vector-based strategies against infectious disease and cancer.Development of replication-deficient adenovirus malaria vaccines.Novel viral vectors in infectious diseases.
P2860
Q26775792-D4BE6375-0F9A-48F8-ADF0-F68435ED162CQ26782083-950BE783-1C58-43D1-A7B9-ED8E6D25C23AQ27024614-95D01B84-FE21-469F-A9B0-E6ED993983E3Q29994714-9D30669E-187C-408F-80B8-FEF6B4C539FFQ30234577-21F21D88-5DA8-4A1F-A1D7-1154985CD0D9Q30370445-861290DF-B8B3-40CD-A67A-CC9209E78A7EQ33630150-AE4198EB-F834-4EBF-9E53-750373A92025Q33645528-6C7C30E7-24CA-4CF3-92AE-ACFD04738A90Q33684288-5B15FA01-AD3E-4EB0-A186-E3E85F1900A5Q33693891-0E140D4F-CA49-4CE8-A4C4-3A3471FBD38FQ34077543-8CB53C2A-5588-407C-8F5A-74D5333C01ABQ34209026-388AF690-9632-43D7-AF98-6ADB095455F0Q34541191-BD2472D8-2477-46F5-BCF5-D52260CB197EQ34991437-3AB60785-3CFA-4C33-9FA7-94899B71FC05Q35055188-4D7F02AF-4CF0-4372-A56A-AB43641D7907Q35557004-AA1FC824-ADAB-43BB-924A-21572B84752EQ35808262-5D1383B0-1B38-467B-84FB-1012AF76ED43Q36192765-609730C2-7F0E-4F71-A569-2483AB368B64Q36211653-587B83AE-2075-4485-BE60-5F1D9AE374B4Q36291682-F04E38A5-B392-4349-8C9C-FEBC44CAE2AFQ36495587-029E47E4-2AE7-442B-919C-9101EB3F2962Q36625165-6FF1352C-B1C4-4A87-8C2F-F443A5285D5CQ37189696-3A290BCA-E477-414D-B3AC-F05A755CE00AQ37277825-96E74A3E-CBE8-4970-A98B-547668B5F5BAQ37621530-6FD43019-1A79-4271-AD67-6C5B374FDB50Q37668399-43D938EB-D97B-40F0-A034-8FB8C10918DDQ37690464-F88A177D-39B5-4C43-BF9B-C1F61F93C4F8Q37718861-8D0F67C6-D5AB-4BF3-9203-D24568952950Q37718956-55DAA09B-8C97-4EA9-BB64-69DEB8B9D35FQ38096490-8082A1BD-51DD-493F-95AB-B2A9B1789271Q38105946-D3F25A1E-B351-494C-A9FB-2FE4795DF551Q38184579-904F0C2A-371E-4B5B-BB94-8447195ACD3EQ38284700-E13257DE-3BA4-481E-B2EF-92098EA568C8Q38577875-CB2FE93A-5F90-4D3C-9D6D-BC6674D14037Q38660339-EF7B9193-8C86-4730-AD1F-A911BE3C27E4Q38670879-7AAC8ACD-5090-4E8B-A928-18C1168419C9Q38712002-5C805599-03DE-4B28-A49B-177794A27B6DQ38814885-CA4DAD58-021B-45E7-93C0-D6B5924432B3Q38949194-361CBCF0-1378-42A6-A8C1-0CEB432D7FD9Q40059020-2F7EA43E-ADA9-4F3B-8A04-26F7E983A39C
P2860
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@ast
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@en
type
label
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@ast
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@en
prefLabel
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@ast
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@en
P2093
P2860
P50
P356
P1476
First-in-human evaluation of t ...... HIV-1 Env vaccine (IPCAVD 001)
@en
P2093
Alka Patel
Ann Cheung
Edith Swann
Elise Zablowsky
Hayley Loblein
James Perry
Jane Kleinjan
Jennifer A Johnson
Katherine E Yanosick
Kathleen H Krause
P2860
P304
P356
10.1093/INFDIS/JIS670
P407
P577
2012-11-02T00:00:00Z